Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLS-0071 in Acute Lung Injury Due to COVID-19 Pneumonia
NCT04574869Phase 1Withdrawn
- Sponsor
- ReAlta Life Sciences
- Start
- Jan 2021
- Primary completion
- Sep 2022
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pegtarazimod in acute lung injury (ALI) and COVID-19 pneumonia (6 arms), sponsored by ReAlta Life Sciences. Primary endpoint: Frequency and severity of Adverse Events at 28 days. Planned start Jan 2021; status: withdrawn.
02
Drugs
pegtarazimod
03
Conditions
acute lung injury (ALI)COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04574869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04574869.